ClinicalTrials.gg
Not yet recruitingNCT07525817Updated Apr 13, 2026

A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

An observational study in Mature B-Cell Lymphoma, sponsored by Ou Bai, MD/PHD. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Ou Bai, MD/PHD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
9th of 10
40 · median 175
Started
2026
with 25 others
Observational
10 of 283
8 open now
Primary completion
2028-04
later than 107 of 145 live
Registered
267th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 26 that started in 2026, is one of 10 observational ones, reaches primary completion later than 107 of the 145 other live ones, and was the 267th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, real-world study to evaluate the efficacy and safety of pirtobrutinib in patients with mature B-cell lymphoma who are resistant or intolerant to prior covalent BTK inhibitors. The primary endpoint is overall response rate (ORR). Secondary endpoints include best overall response (BOR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. A total of 40 patients will be enrolled across 8 centers in China.

Read the detailed description

This prospective, multicenter, observational real-world study enrolls 40 patients with histologically confirmed mature B-cell lymphoma who have failed or are intolerant to at least one covalent BTK inhibitor. Patients receive pirtobrutinib 200 mg once daily until disease progression or unacceptable toxicity. Efficacy is assessed per Lugano 2014, iwCLL 2018, and IWWM-11 criteria. Safety is evaluated using CTCAE v5.0. The primary outcome is ORR. Secondary outcomes include BOR, DOR, PFS, OS, and safety profile.

03

Conditions studied

  • Mature B-Cell Lymphoma

Browse trials for

Keywords

  • Pirtobrutinib
  • Covalent BTK inhibitor
  • Mature B-cell lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study enrolls 40 adult patients (≥18 years old) with histologically confirmed mature B-cell lymphoma who are resistant or intolerant to at least one prior covalent BTK inhibitor (cBTKi) therapy, across 8 clinical centers in China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Histopathological confirmation of mature B-cell lymphoma, primarily including CLL/SLL, MCL, FL, MZL, WM/LPL, etc.;
  • Disease progression and/or intolerance after prior treatment with ≥1 cBTKi (including ibrutinib, ibrutinib, zanubrutinib, or acitinib);
  • PS 0-2;
  • Adequate liver and kidney function: the following criteria must be met simultaneously: 1) and ALT ≤ 3×; 2) Total ≤ 1.5×ULN; 3) rate ≥ 30 mL/min;
  • Participants must be voluntary and capable of completing the study procedures and follow-up examinations;
  • must be obtained voluntarily prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergic reactions to any component or of piteutinib;
  • Patients concurrently participating in other clinical studies;
  • A history of , uncontrolled cardiac,
  • Cardiovascular disease, or myocardial infarction within 6 months prior to planned initiation of piteutinib therapy;
  • Uncontrolled systemic bacterial, viral, fungal, or parasitic infections; current use of potent inhibitors or inducers and/or potent P-gp inhibitors;
  • Positive (HIV) testing;
  • Active or C: 1) Patients with positive hepatitis B virus (HBV) DNA testing and controlled disease status may be enrolled with investigator approval. For HBV DNA-positive patients, concurrent antiviral therapy is required. 2) Patients with prior virus (HCV) infection history who have completed antiviral therapy with viral loads below the quantitative limit may be enrolled;
  • Based on the investigator's assessment, participants may be unable to complete all study protocol requirements, including follow-up visits, and/or adhere to all study procedures;
  • A history of other clinically significant diseases or comorbidities; and any safety risks or potential interference with study completion as evaluated by investigators.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pirtobrutinib Treatment Cohort

    Patients with cBTKi-resistant/intolerant mature B-cell lymphoma receiving pirtobrutinib 200 mg once daily in real-world clinical practice.Receive pitobrutinib as monotherapy or in combination, with a recommended dose of 200 mg once daily until disease progression or unacceptable toxicity occurs.

    Drug: Pirtobrutinib

Interventions

  • Pirtobrutinib 200 mg administered orally once daily, in accordance with standard clinical practice, until disease progression, unacceptable toxicity, or study completion.

06

What researchers measure

Primary outcomes

  1. ORR

    Overall Response Rate

    Time frame: 24months

Secondary outcomes

  1. BOR

    Best Overall Response

    Time frame: 24 months

  2. DOR

    Duration of Response

    Time frame: 24 months

  3. PFS

    Progression-Free Survival

    Time frame: 24 months

  4. OS

    Overall Survival

    Time frame: 24 months

  5. Number of participants with treatment-related adverse events (TRAEs) as assessed by CTCAE v5.0

    Incidence, severity (graded per CTCAE v5.0), and causality of all adverse events (AEs), serious adverse events (SAEs), and treatment-related adverse events (TRAEs) from the first dose of pirtobrutinib to 30 days after the last dose.

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 13, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07525817
Lead sponsor
Ou Bai, MD/PHD
Responsible party
Ou Bai, MD/PHD (Principal Investigator, Professor, The First Hospital of Jilin University) — Sponsor-investigator
First posted
Apr 13, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Ou BAI, MD, PhD
Contact
oubai16@163.com
+86-13039046656
Jia Li, MD
Contact
lijia0810@jlu.edu.cn
+86 13844898514

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion